PROTOKOLwiki
COMPOUNDS / PSYCHEDELIC / IBOGAINE
PSYCHEDELIC

IBOGAINE

HIGH RISK
BEST FOR:Addiction Recovery●●●●●●●○○○7/10
IBOGAINE · IBOGA · TABERNANTHE IBOGA · ENDABUSE · NORIBOGAINE (METABOLITE)
PsychedelicAnti-addictiveOneirogenIndole AlkaloidOpioid Withdrawal

A psychoactive indole alkaloid from the African iboga plant, investigated for opioid dependence and trauma-related disorders.

ROUTE / DOSAGE
LOW5mg/kg
STANDARD10-20mg/kg
HIGH25mg/kg+
Note: Therapeutic doses calculated by body weight; cardiac monitoring essential due to QT prolongation risk
CYCLE
Single session typically weeks to months apart
BIOAVAILABILITY
low oral (~5-10%)
ACTIVE DURATION
12-24h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
7-10h (ibogaine) 28-49h (noribogaine) (plasma)
DURATION BREAKDOWN
Total12-36 hours
Onset30min-3h
Come up1-3h
Peak4-8h
Offset8-24h
After effects24-72h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Reduction of opioid withdrawal symptoms
Vivid dream-like visionary experiences
Decreased drug cravings
Cerebellar ataxia and motor impairment
QT interval prolongation
Altered perception of time
Dissociative states
Oneiric (dream-like) hallucinations
§ 02 — RISKS
Fatal cardiac arrhythmias and sudden cardiac arrest via hERG potassium channel blockade
QT interval prolongation leading to ventricular tachyarrhythmias even in individuals without pre-existing cardiovascular conditions
Neurotoxicity including cerebellar Purkinje cell degeneration
At least 27 reported fatalities following ibogaine ingestion
Dangerous drug-drug interactions via CYP2D6 metabolism polymorphism
Headaches and cerebellar ataxia during treatment
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

A systematic review of 24 studies including 705 individuals found ibogaine effective in reducing withdrawal symptoms and craving in substance use disorders, with beneficial effects on depressive and trauma-related symptoms. A 12-month observational study showed significant reductions in opioid withdrawal and drug use severity following a single treatment. A 2024 prospective study of magnesium-ibogaine therapy in veterans with TBI showed significant improvements in disability, PTSD, depression, and anxiety with no serious adverse events. However, evidence is limited by small sample sizes, lack of controlled trials, and significant safety concerns including at least 27 reported fatalities. Cardiotoxicity via hERG channel blockade causing QT prolongation and arrhythmias remains the primary barrier to clinical development.

§ 06 — SOURCES
[1]
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
pubmed.ncbi.nlm.nih.gov ↗
[2]
Magnesium-ibogaine therapy in veterans with traumatic brain injuries
pubmed.ncbi.nlm.nih.gov ↗
[3]
A systematic literature review of clinical trials and therapeutic applications of ibogaine
pubmed.ncbi.nlm.nih.gov ↗
[4]
Ibogaine: a review
pubmed.ncbi.nlm.nih.gov ↗
[5]
How toxic is ibogaine?
pubmed.ncbi.nlm.nih.gov ↗
[6]
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review
pubmed.ncbi.nlm.nih.gov ↗
[7]
Ibogaine in the treatment of substance dependence
pubmed.ncbi.nlm.nih.gov ↗
[8]
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Ibogaine
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT